What's Happening?
Skape Bio, a biotechnology company, has launched a new platform for designing protein-based medicines targeting G protein-coupled receptors (GPCRs), a significant class of drug targets. This platform, developed in collaboration with the University of Washington's
Institute for Protein Design, utilizes AI-enabled protein design and high-throughput screening in living human cells. The system can evaluate up to 100,000 protein designs, maintaining the receptors in their natural membrane environment, which is crucial for accurate signaling. This approach addresses the limitations of traditional methods that often require removing receptors from the cell membrane. The platform has already generated functional lead molecules against 11 GPCR targets, including those related to cancer and metabolic diseases.
Why It's Important?
The development of this platform is significant as GPCRs are involved in many common diseases, and about one-third of approved drugs target these receptors. However, designing biologic medicines for GPCRs has been challenging due to their flexible, membrane-embedded shapes. Skape Bio's platform offers a more precise method for developing protein therapeutics, potentially leading to more effective and safer drugs. This innovation could transform the pharmaceutical industry by expanding the range of GPCRs that can be targeted with protein-based medicines, offering new treatment options for diseases where current drug modalities are inadequate.
What's Next?
Skape Bio plans to advance its internal pipeline and partner with pharmaceutical companies to apply its platform across various disease areas. The company is also expanding its team in Copenhagen to support these efforts. As the platform gains traction, it could lead to the development of a new generation of precision protein therapeutics, potentially revolutionizing the treatment of diseases associated with GPCRs.
